ClinicalTrials.gg
RecruitingNCT07110714HydroCoVitalBUpdated Dec 2, 2025

Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients

An interventional study of Cold water hydrotherapy in Post COVID-19 Condition, Post COVID-19 Condition (PCC) and Post COVID-19, sponsored by Eggensberger OHG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Eggensberger OHG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Planned enrollment
27th of 28
30 · median 108
Started
2025
with 6 others
No phase
20 of 41
7 open now
Primary completion
2027-01
later than 8 of 16 live
Registered
37th of 41
by date

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 27th largest by planned enrollment of the 28 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 with no phase, reaches primary completion later than 8 of the 16 other live ones, and was the 37th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.

Read the detailed description

Patients recovering from Post-COVID Syndrome often experience persistent fatigue, autonomic dysregulation, microcirculatory disturbances, and low-grade inflammation, all of which may hinder their return to full function. Kneipp hydrotherapy-using cold water applications-can address these pathophysiological changes through several mechanisms:

Autonomic regulation: Cold stimuli trigger parasympathetic activation and improve sympathovagal balance, helping to stabilize heart rate variability and reduce symptoms of dysautonomia often seen in Post-COVID.

Enhanced microcirculation: Repeated vasoconstriction and reactive vasodilation promote endothelial function and tissue perfusion, which may alleviate muscle aches, dizziness, and fatigue by improving oxygen and nutrient delivery.

Anti-inflammatory effects: Hydrothermal stimuli have been shown to modulate cytokine profiles, increasing anti-inflammatory mediators and potentially dampening the persistent, low-grade inflammation implicated in Post-COVID pathophysiology.

Musculoskeletal recovery: Thermo-mechanical stimulation relaxes tense muscle fibers, reduces pain perception, and supports gradual increases in physical capacity, all of which are important for overcoming Post-COVID deconditioning.

Taken together, these effects suggest that adjunctive cold water hydrotherapy could accelerate functional recovery, reduce symptom burden, and enhance quality of life in Post-COVID rehabilitation.

Baseline Assessments:

At baseline, demographic data including sex, age, height, and weight will be collected. Participants will report their current main Post-COVID symptoms, which will be categorized into symptom clusters: Fatigue (A), Cognitive (B), and Somatic (C). Smoking history will be assessed, including smoking status (current, former, or never), number of cigarettes per day, years of smoking, and pack-years.

The time (in months) since the COVID-19 infection that led to Post-COVID syndrome will be documented, along with the number of COVID-19 vaccinations received at the time of infection. Employment status will be recorded, distinguishing between full-time or part-time employment, COVID-related work disability, retirement, unemployment, or disability pension.

Comorbidities will be documented across the following categories: cardiovascular, pulmonary, cerebrovascular, metabolic, musculoskeletal, psychiatric, and other conditions. The severity of the acute COVID-19 illness will be assessed using the WHO Clinical Progression Scale, including information on any hospital admission and length of stay (in days).

Autonomic function testing at baseline (V1) will be evaluated using the Schellong test. Additionally, self-reported work ability and the number of Post-COVID-related sick leave days within the past 12 weeks will be recorded.

03

Conditions studied

  • Post COVID-19 Condition
  • Post COVID-19 Condition (PCC)
  • Post COVID-19
  • Post COVID-19 Syndrome
  • Long COVID-19 Syndrome

Keywords

  • therapy
  • intervention
  • hydrotherapy
  • Kneipp
  • balneotherapy
  • quality of life
  • PCC
  • long COVID
  • post COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)
  • Barthel-Index >80
  • Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability
  • Written

Exclusion criteria

Exclusion Criteria:

  • Existing for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)
  • Prior regular practice of Kneipp applications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Post-COVID treatment with hydrotherapy

    Cold water hydrotherapy (5-10 minutes each), four times daily during the 3-week program and once daily during the 6- month follow-up period. During the 3-week stay, standard medical care is provided by registered doctors as needed.

    Other: Cold water hydrotherapy

  • No intervention
    Usual care setting

    Usual care setting at home with no hydrotherapy interventions.

Interventions

  • OtherCold water hydrotherapy

    Cold water hydrotherapy (5-10 minutes each), four times daily during the 3-week program and once daily during the 6-month follow-up period. Hydrotherapy interventions are individually tailored to each subject based on their responses and include various washing and pouring techniques.

06

What researchers measure

Primary outcomes

  1. Health-related quality of life by Short Form-12 Health Survey (SF-12)

    Change in the Short Form-12 physical and mental component summary scores (minimum score = 0; maximum score = 100; higher scores indicate higher health-related quality of life)

    Time frame: From baseline (Visit 1) to end of 3-week program (3 weeks, Visit 2)

Secondary outcomes

  1. Fatigue severity by Fatigue Severity Scale

    Change in Fatigue Severity Scale score (minimum score = 9; maximum score = 63; higher scores indicate greater fatigue severity)

    Time frame: From baseline (Visit 1) to end of 3-week program (3 weeks, Visit 2)

  2. Sleep quality by Pittsburgh Sleep Quality Index

    Change in Pittsburgh Sleep Quality Index score (minimum score = 0; maximum score = 21; higher scores indicate poorer sleep quality)

    Time frame: From baseline (Visit 1) to end of 3-week program (3 weeks, Visit 2)

  3. Health status by EuroQol-5 Dimensions-5 Levels

    Change in EuroQol-5 Dimensions-5 Levels questionnaire score (score represented by a 5-digit code; each digit represents one dimension, ranging from 1 to 5; higher digits indicate poorer health state)

    Time frame: From baseline (Visit 1) to end of 3-week program (3 weeks, Visit 2)

  4. Autonomic function (heart rate variability by photoplethysmography)

    Change in heart rate variability (root mean square of successive differences) measured by Kyto 2935 via photoplethysmography

    Time frame: Daily during the 3-week program (Visit 1 to Visit 2)

  5. Resting blood pressure (systolic and diastolic)

    Change in morning resting systolic and diastolic blood pressure

    Time frame: Daily during first 3 weeks of rehabilitation (Visit 1 to Visit 2)

  6. Post-COVID work-absence days

    Number of days of work absence due to Post-COVID-19 symptoms during the past 12-weeks

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  7. Long-term quality of life by Short Form-12 Health Survey

    Change in Short Form-12 scores at follow-up (minimum score = 0; maximum score = 100; higher scores indicate higher health-related quality of life)

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  8. Long-term fatigue by Fatigue Severity Scale

    Change in Fatigue Severity Scale score at follow-up (minimum score = 9; maximum score = 63; higher scores indicate greater fatigue severity)

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  9. Adherence to hydrotherapy

    Proportion of prescribed hydrotherapy applications in the intervention group performed, as recorded in diary or app. Short-term Adherence: During the 3-week intervention phase, patients are considered "adherent" if they perform atleast one hydrotherapy session per day on at least 75% of study days. The investigators will compare health improvements between high-adherence and low-adherence participants. Long-term Adherence and Effects: Over the 3- and 6-month follow-up, "adherent" patients are those who continue self administered hydrotherapy at least four times per week on at least 75% of follow-up weeks. The investigators will assess whether these patients sustain greater gains in quality of life.

    Time frame: During the 3-week intervention phase (up to Visit 2) and over the 6-month follow-up period (to Visit 4)

  10. Adverse events recording

    Number and severity of adverse events related to Kneipp hydrotherapy

    Time frame: From start of intervention (Visit 1) through end of study (Visit 4, 6-month follow-up)

  11. Long-term heart rate variability changes (HRV)

    Change in heart rate variability parameters (root mean square of successive differences) measured by photoplethysmography. At follow-up visits patients will measure HRV for 7 consecutive days

    Time frame: From baseline (Visit 1) to 3 months (Visit 3) and to 6 months (Visit 4)

  12. Post-exertional malaise severity

    Change in Post-Exertional Malaise score measured by the DePaul Symptom Questionnaire-Post-Exertional Malaise

    Time frame: From baseline (Visit 1) to 6-month (Visit 4) follow-up

  13. Daily well-being documentation

    Self-reported daily well-being recorded via digital diary on a scale from 0 to 100

    Time frame: Daily throughout the intervention and 6 months follow-up phase (Visit 1 to Visit 4)

07

Study locations

1 of 1 sites recruiting
  • Eggensberger Ohg
    Füssen, Bavaria D-87629, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

Of 243 interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 8, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110714
Lead sponsor
Eggensberger OHG
Collaborators
Bavarian Health and Food Safety Authority (LGL)
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Dec 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Andreas Eggensberger, MSc
Contact
a.eggensberger@eggensberger.de
+4983629103300
Rembert Koczulla, MD
principal investigator · Schön Klinik Berchtesgadener Land

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion